Literature DB >> 25830818

Epidemiology of irritable bowel syndrome.

Yuka Endo1, Tomotaka Shoji1, Shin Fukudo1.   

Abstract

Entities:  

Year:  2015        PMID: 25830818      PMCID: PMC4367204     

Source DB:  PubMed          Journal:  Ann Gastroenterol        ISSN: 1108-7471


× No keyword cloud information.
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by chronic abdominal symptoms in the absence of major mechanical, inflammatory, or biochemical diseases as determined by routine clinical examinations [1]. In the Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders, IBS is defined by abdominal pain or discomfort associated with at least two of the following: symptom relief by defecation; symptoms associated with changes in defecation frequency; and symptoms associated with changes in stool form [1]. IBS is classified into four subtypes according to predominant stool consistency: IBS with constipation (IBS-C); IBS with diarrhea (IBS-D); mixed IBS (IBS-M); and unsubtyped IBS (IBS-U). IBS is not a fatal disease but it does greatly reduce quality of life [2,3]. It was reported that approximately 10-20% of adults in Western countries have IBS symptoms [4,5] and a similar prevalence has been reported in Asia [6-8]. Recently, Lovell and Ford conducted a meta-analysis of studies on the epidemiology of IBS [9] and estimated a global prevalence of 11.2% (95% confidence interval [CI], 9.8-12.8%), a rate that has not changed in the last 30 years. Moreover, they found that the odds ratio of IBS in women has only modestly increased compared with men and that socioeconomic status did not show any effect on prevalence, though there are some conflicting results. Globally, Southeast Asia has lowest prevalence of IBS (7.0%) and South America the highest (21.0%). Regrettably, the prevalence in Africa is not clear as there have been few population-based studies. Such studies are needed in the countries that lack precise epidemiological data. The criteria used to define IBS greatly influence prevalence estimates. In this journal, Keshteli et al reported a prevalence of 21.5% in Iranian adults based on the modified Rome III criteria [10]. However, the prevalence in Iran was only 9.0% (95% CI, 6.0-13.0) based on the Rome II criteria [9]. Moreover, IBS prevalence differs among Western countries even when the same diagnostic criteria are used. For example, France has a lower IBS prevalence than America. From this meta-analysis by Lovell and Ford [9], IBS-D was the most prevalent (40.0%), followed by IBS-C (35.0%) and IBS-M (23.0%). IBS is frequently seen in adolescents. According to Lovell and Ford’s meta-analysis [9], its prevalence appears to decline modestly with increasing age. While individuals aged 50 years or older do have a lower odds ratio for IBS than those younger than 50, the prevalence of IBS was reported to be almost the same in adolescents as in adults [11-13]. Indeed, in our data [11], the prevalence in students aged 15 years was 14.6% in 2004 and 19% in 2009, with girls showing higher prevalence than boys in both years. Students with IBS exhibited lower health-related quality of life and lower self-efficacy, and reported more sleep disturbance, traumatic episodes, and perceived stress than students without abdominal symptoms. Students with IBS also had alexithymic tendencies, which worsened symptoms. These features are also seen in adult IBS. Further studies are needed to determine whether these features are causes or consequences of IBS. Some subjects with acute infectious gastroenteritis develop a subtype of IBS termed post-infectious IBS (PI-IBS). In a meta-analysis, Halvorson et al reported a PI-IBS prevalence of 9.8% (odds ratio, 7.3) [14]. Thabane et al reported that the odds ratio of PI-IBS was 5.86 and that its prevalence decreased with increasing years after acute gastroenteritis [15]. It is thought that the risk of developing PI-IBS is high within a few years after gastroenteritis. While these reports analyzed only bacterial gastroenteritis, high prevalence of PI-IBS after viral gastroenteritis has also been reported [16]. PI-IBS accounts for about 5-25% of all IBS cases [17,18]. In our data from a survey of patients during routine medical examinations, the ratio of past gastroenteritis was 16.1% in controls, 32.6% in IBS non-consulters, and 44.6% in IBS patients [6]. There is now little doubt that infectious gastroenteritis is one of the risk factors for developing IBS. Taken together, epidemiological features of IBS are affected by many factors including diagnostic criteria, age, sex/gender, and post-infectious episodes. Moreover, culture likely plays an important role in the features of IBS. There are some remaining challenges in establishing an accurate epidemiology of IBS, but doing so will provide a key to treating this common syndrome around the world.
  17 in total

1.  An epidemiologic study of irritable bowel syndrome in adolescents and children in South China: a school-based study.

Authors:  H Zhou; D Li; G Cheng; J Fan; H Lu
Journal:  Child Care Health Dev       Date:  2010-11       Impact factor: 2.508

2.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

Authors:  Rebecca M Lovell; Alexander C Ford
Journal:  Clin Gastroenterol Hepatol       Date:  2012-03-15       Impact factor: 11.382

3.  The features of adolescent irritable bowel syndrome in Japan.

Authors:  Yuka Endo; Tomotaka Shoji; Shin Fukudo; Tomomi Machida; Takatsugu Machida; Satoko Noda; Michio Hongo
Journal:  J Gastroenterol Hepatol       Date:  2011-04       Impact factor: 4.029

4.  Frequency of irritable bowel syndrome, entrance examination-related stress, mental health, and quality of life in high school students.

Authors:  Hyojung Park; Sunyoung Lim
Journal:  Gastroenterol Nurs       Date:  2011 Nov-Dec       Impact factor: 0.978

5.  Postinfectious irritable bowel syndrome--a meta-analysis.

Authors:  Heather A Halvorson; Carey D Schlett; Mark S Riddle
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

6.  Epidemiology of irritable bowel syndrome in Chinese.

Authors:  E M C Lau; F K L Chan; E T C Ziea; C S Y Chan; J C Y Wu; J J Y Sung
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

7.  The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population.

Authors:  Chad K Porter; Robert Gormley; David R Tribble; Brooks D Cash; Mark S Riddle
Journal:  Am J Gastroenterol       Date:  2010-09-21       Impact factor: 10.864

8.  Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.

Authors:  F Creed; J Ratcliffe; L Fernandez; B Tomenson; S Palmer; C Rigby; E Guthrie; N Read; D Thompson
Journal:  Ann Intern Med       Date:  2001-05-01       Impact factor: 25.391

Review 9.  The epidemiology of irritable bowel syndrome in North America: a systematic review.

Authors:  Yuri A Saito; Philip Schoenfeld; G Richard Locke
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

10.  Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults.

Authors:  Ammar Hassanzadeh Keshteli; Babak Dehestani; Hamed Daghaghzadeh; Peyman Adibi
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun
View more
  20 in total

1.  Utilizing Google Trends to Assess Worldwide Interest in Irritable Bowel Syndrome and Commonly Associated Treatments.

Authors:  Ryan Flanagan; Braden Kuo; Kyle Staller
Journal:  Dig Dis Sci       Date:  2020-05-02       Impact factor: 3.199

2.  Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome.

Authors:  Ravichandran Gayathri; Thangavelu Aruna; Sivaraman Malar; Bennur Shilpa; Karukkupalayam Ramasamy Dhanasekar
Journal:  Int J Colorectal Dis       Date:  2019-12-05       Impact factor: 2.571

3.  Alterations to microbial secretome by estrogen may contribute to sex bias in irritable bowel syndrome.

Authors:  Lesha Pretorius; Anton du Preez Van Staden; Johannes J Van der Merwe; Natasha Henning; Carine Smith
Journal:  Inflammopharmacology       Date:  2022-01-13       Impact factor: 4.473

Review 4.  Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Authors:  Theodor Bokic; Martin Storr; Rudolf Schicho
Journal:  Pharmacology       Date:  2015-07-01       Impact factor: 2.547

5.  The relationship between dietary intakes and prevalence of irritable bowel syndrome in adolescent girls: A cross-sectional study.

Authors:  Fatemeh Roudi; Sayyed Saeid Khayyatzadeh; Hamideh Ghazizadeh; Gordon A Ferns; Hamidreza Bahrami-Taghanaki; Mohammad Mohammad-Zadeh; Majid Ghayour-Mobarhan
Journal:  Indian J Gastroenterol       Date:  2021-03-05

Review 6.  The Microbiota-Gut-Brain Axis: From Motility to Mood.

Authors:  Kara G Margolis; John F Cryan; Emeran A Mayer
Journal:  Gastroenterology       Date:  2021-01-22       Impact factor: 22.682

Review 7.  Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.

Authors:  Konstantinos C Fragkos
Journal:  Clin Exp Gastroenterol       Date:  2017-09-25

8.  Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics.

Authors:  Dorottya Nagy-Szakal; Dinesh K Barupal; Bohyun Lee; Xiaoyu Che; Brent L Williams; Ellie J R Kahn; Joy E Ukaigwe; Lucinda Bateman; Nancy G Klimas; Anthony L Komaroff; Susan Levine; Jose G Montoya; Daniel L Peterson; Bruce Levin; Mady Hornig; Oliver Fiehn; W Ian Lipkin
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

9.  The Protective Effect of Melissa officinalis L. in Visceral Hypersensitivity in Rat Using 2 Models of Acid-induced Colitis and Stress-induced Irritable Bowel Syndrome: A Possible Role of Nitric Oxide Pathway.

Authors:  Fatemeh Dolatabadi; Amir H Abdolghaffari; Mohammad H Farzaei; Maryam Baeeri; Fatemeh S Ziarani; Majid Eslami; Mohammad Abdollahi; Roja Rahimi
Journal:  J Neurogastroenterol Motil       Date:  2018-07-30       Impact factor: 4.924

10.  Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut-Directed Hypnotherapy.

Authors:  Johannes Peter; Camille Fournier; Bettina Keip; Nina Rittershaus; Nicola Stephanou-Rieser; Marija Durdevic; Clemens Dejaco; Maria Michalski; Gabriele Moser
Journal:  Int J Mol Sci       Date:  2018-11-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.